Lu-Dota-Tyr-Octreotat, C41030610-041 Efficacy of Peptide Receptor Radionuclide Therapy for Metastatic Inoperable Neuroendocrine Tumors Using 177-Lu-DOTA 0, Tyr 3 Octreotate (Aktiv)
Zweitlinie oder später
AIO-NET-0117/ass - RamuNet A study to investigate the efficacy of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic neuroendocrine tumors of the pancreas (Aktiv)